skip to main content
OSTI.GOV title logo U.S. Department of Energy
Office of Scientific and Technical Information

Title: Proton Radiation Therapy for the Treatment of Retinoblastoma

Abstract

Purpose: To investigate long-term disease and toxicity outcomes for pediatric retinoblastoma patients treated with proton radiation therapy (PRT). Methods and Materials: This is a retrospective analysis of 49 retinoblastoma patients (60 eyes) treated with PRT between 1986 and 2012. Results: The majority (84%) of patients had bilateral disease, and nearly half (45%) had received prior chemotherapy. At a median follow-up of 8 years (range, 1-24 years), no patients died of retinoblastoma or developed metastatic disease. The post-PRT enucleation rate was low (18%), especially in patients with early-stage disease (11% for patients with International Classification for Intraocular Retinoblastoma [ICIR] stage A-B disease vs 23% for patients with ICIR stage C-D disease). Post-PRT ophthalmologic follow-up was available for 61% of the preserved eyes (30 of 49): 14 of 30 eyes (47%) had 20/40 visual acuity or better, 7 of 30 (23%) had moderate visual acuity (20/40-20/600), and 9 of 30 (30%) had little or no useful vision (worse than 20/600). Twelve of 60 treated eyes (20%) experienced a post-PRT event requiring intervention, with cataracts the most common (4 eyes). No patients developed an in-field second malignancy. Conclusions: Long-term follow-up of retinoblastoma patients treated with PRT demonstrates that PRT can achieve high local control rates, evenmore » in advanced cases, and many patients retain useful vision in the treated eye. Treatment-related ocular side effects were uncommon, and no radiation-associated malignancies were observed.« less

Authors:
 [1]; ; ; ; ; ; ; ;  [2];  [3];  [4]
  1. Harvard Radiation Oncology Program, Boston, Massachusetts (United States)
  2. Department of Radiation Oncology, Massachusetts General Hospital, Boston, Massachusetts (United States)
  3. Department of Pediatrics, Massachusetts General Hospital, Boston, Massachusetts (United States)
  4. Retina Service, Department of Ophthalmology, Massachusetts Eye and Ear Infirmary, Boston, Massachusetts (United States)
Publication Date:
OSTI Identifier:
22420475
Resource Type:
Journal Article
Journal Name:
International Journal of Radiation Oncology, Biology and Physics
Additional Journal Information:
Journal Volume: 90; Journal Issue: 4; Other Information: Copyright (c) 2014 Elsevier Science B.V., Amsterdam, The Netherlands, All rights reserved.; Country of input: International Atomic Energy Agency (IAEA); Journal ID: ISSN 0360-3016
Country of Publication:
United States
Language:
English
Subject:
62 RADIOLOGY AND NUCLEAR MEDICINE; CATARACTS; CHEMOTHERAPY; CLASSIFICATION; EYES; METASTASES; NEOPLASMS; PATIENTS; PEDIATRICS; PROTON BEAMS; RADIOTHERAPY; SIDE EFFECTS; TOXICITY; VISION

Citation Formats

Mouw, Kent W., Department of Radiation Oncology, Massachusetts General Hospital, Boston, Massachusetts, Sethi, Roshan V., Yeap, Beow Y., MacDonald, Shannon M., Chen, Yen-Lin E., Tarbell, Nancy J., Yock, Torunn I., Munzenrider, John E., Adams, Judith, Grabowski, Eric, Mukai, Shizuo, and Shih, Helen A., E-mail: hshih@partners.org. Proton Radiation Therapy for the Treatment of Retinoblastoma. United States: N. p., 2014. Web. doi:10.1016/J.IJROBP.2014.07.031.
Mouw, Kent W., Department of Radiation Oncology, Massachusetts General Hospital, Boston, Massachusetts, Sethi, Roshan V., Yeap, Beow Y., MacDonald, Shannon M., Chen, Yen-Lin E., Tarbell, Nancy J., Yock, Torunn I., Munzenrider, John E., Adams, Judith, Grabowski, Eric, Mukai, Shizuo, & Shih, Helen A., E-mail: hshih@partners.org. Proton Radiation Therapy for the Treatment of Retinoblastoma. United States. https://doi.org/10.1016/J.IJROBP.2014.07.031
Mouw, Kent W., Department of Radiation Oncology, Massachusetts General Hospital, Boston, Massachusetts, Sethi, Roshan V., Yeap, Beow Y., MacDonald, Shannon M., Chen, Yen-Lin E., Tarbell, Nancy J., Yock, Torunn I., Munzenrider, John E., Adams, Judith, Grabowski, Eric, Mukai, Shizuo, and Shih, Helen A., E-mail: hshih@partners.org. 2014. "Proton Radiation Therapy for the Treatment of Retinoblastoma". United States. https://doi.org/10.1016/J.IJROBP.2014.07.031.
@article{osti_22420475,
title = {Proton Radiation Therapy for the Treatment of Retinoblastoma},
author = {Mouw, Kent W. and Department of Radiation Oncology, Massachusetts General Hospital, Boston, Massachusetts and Sethi, Roshan V. and Yeap, Beow Y. and MacDonald, Shannon M. and Chen, Yen-Lin E. and Tarbell, Nancy J. and Yock, Torunn I. and Munzenrider, John E. and Adams, Judith and Grabowski, Eric and Mukai, Shizuo and Shih, Helen A., E-mail: hshih@partners.org},
abstractNote = {Purpose: To investigate long-term disease and toxicity outcomes for pediatric retinoblastoma patients treated with proton radiation therapy (PRT). Methods and Materials: This is a retrospective analysis of 49 retinoblastoma patients (60 eyes) treated with PRT between 1986 and 2012. Results: The majority (84%) of patients had bilateral disease, and nearly half (45%) had received prior chemotherapy. At a median follow-up of 8 years (range, 1-24 years), no patients died of retinoblastoma or developed metastatic disease. The post-PRT enucleation rate was low (18%), especially in patients with early-stage disease (11% for patients with International Classification for Intraocular Retinoblastoma [ICIR] stage A-B disease vs 23% for patients with ICIR stage C-D disease). Post-PRT ophthalmologic follow-up was available for 61% of the preserved eyes (30 of 49): 14 of 30 eyes (47%) had 20/40 visual acuity or better, 7 of 30 (23%) had moderate visual acuity (20/40-20/600), and 9 of 30 (30%) had little or no useful vision (worse than 20/600). Twelve of 60 treated eyes (20%) experienced a post-PRT event requiring intervention, with cataracts the most common (4 eyes). No patients developed an in-field second malignancy. Conclusions: Long-term follow-up of retinoblastoma patients treated with PRT demonstrates that PRT can achieve high local control rates, even in advanced cases, and many patients retain useful vision in the treated eye. Treatment-related ocular side effects were uncommon, and no radiation-associated malignancies were observed.},
doi = {10.1016/J.IJROBP.2014.07.031},
url = {https://www.osti.gov/biblio/22420475}, journal = {International Journal of Radiation Oncology, Biology and Physics},
issn = {0360-3016},
number = 4,
volume = 90,
place = {United States},
year = {Sat Nov 15 00:00:00 EST 2014},
month = {Sat Nov 15 00:00:00 EST 2014}
}